Microbix Biosystems Inc (MBX) Fair Value & Analysis
Healthcare · CA · Market cap C$37.1M
Fair value as of: Jun 25, 2026
From 2 valuation models · updated 4 days ago
Fair value updated Jun 25, 2026 — revised from C$0.9100 to C$0.0600 (−93.4%) since Jun 24, 2026. Share price +9.3% over the past month.
Price vs Fair Value (12 months)
12‑month range C$0.2064 – C$0.3047 · fair‑value band C$0.0500 – C$0.0600 · the C$0.2900 price screens above the C$0.0600 fair value. As of Jun 25, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Microbix Biosystems Inc (MBX) currently trades at C$0.2900, while our model-based Fair Value estimate is C$0.0600 — implying the stock looks roughly 79.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Microbix Biosystems Inc generated revenue of C$14.8M at a net margin of -38.6%. Revenue declined 36.6% year over year. It earns a return on equity of -20.4%. The balance sheet holds a net cash position of C$5.3M. Fundamentals as of Jun 25, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 25, 2026. TTM = trailing twelve months.
About the company
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures a wide range of critical biological materials and medical devices for the global diagnostics industry, notably test ingredients (Antigen business) used in immunoassays, quality assessment, and diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for enabling the collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. It also provides customer vial filling services. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Microbix Biosystems Inc reported revenue of C$18.6M in FY2025 versus C$18.6M in FY2021, a compound −0.0%/yr. Reported net income was −C$2.2M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$562.61 | R$385.38 | -32% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $286.41 | $106.81 | -63% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Microbix Biosystems Inc (MBX) undervalued?
What is the fair value of MBX?
What is the quality score of MBX?
What is the revenue of Microbix Biosystems Inc (MBX)?
What is the net profit margin of MBX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.